文献速递肾小球疾病急性肾损伤

狼疮性肾炎随机对照试验的外部有效性系统评价

Systematic Review and the External Validity of Randomized Controlled Trials in Lupus Nephritis.
PubMed 文献 · Kidney Int Rep · 2017-11-16

该研究系统检索1974至2015年狼疮性肾炎诱导治疗RCT,并将Barts狼疮中心1995至2013年137例新诊断患者与各RCT入组标准比对。结果显示32%患者会被排除(范围8%-73%),主要原因包括病情过重、过轻或既往免疫抑制剂使用;因复发再活检的27例中68%也不符合入组条件。

要点

  • 常规实践中约三分之一狼疮性肾炎患者不符合已发表RCT入组标准。
  • 排除主因为病情过重、过轻或既往免疫抑制剂使用。
  • 因复发再活检患者中68%亦不符合RCT入组条件。

核心结论

  • 已发表的狼疮性肾炎RCT不能真实反映常规实践中患者的异质性。
  • RCT结果应作为指南,但治疗决策前需考虑个体患者与试验队列特征的相似性。

研究设计与样本

  • 系统文献检索1974年1月至2015年5月,纳入所有狼疮性肾炎诱导治疗RCT。
  • 从Barts狼疮中心数据库识别1995至2013年诊断的增殖性或膜性狼疮性肾炎患者。
  • 将患者基线特征与每个RCT入组标准比对,评估假设性纳入或排除。

主要发现

  • 363篇文章中33项RCT符合纳入标准。
  • 137例新诊断狼疮性肾炎患者中111例为增殖性/混合增殖性,26例为单纯膜性。
  • 32%患者会被排除出RCT入组(范围8%-73%)。
  • 排除主因为病情过重、病情过轻或既往免疫抑制剂使用,分别见于26、20和22项RCT的排除标准。
  • 27例(20%)患者因复发再活检,其中68%不符合RCT入组条件。

临床怎么用

  • 应用RCT证据时需评估个体患者与试验队列特征的相似性。
  • RCT结果可作为治疗指导,但需考虑常规实践中患者异质性。

局限性

  • 研究基于单中心Barts狼疮中心数据库,外部推广需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Randomized controlled trials (RCTs) are considered the gold standard for assessing treatment efficacy. However, sampling bias can affect the generalization of results to routine clinical practice. Here we assessed whether patients with lupus nephritis (LN) seen in routine clinical practice would have satisfied entry criteria to the major published RCTs in LN. METHODS: A systematic literature search from January 1974 to May 2015 was carried out, identifying all RCTs investigating LN induction treatment. Patients diagnosed with proliferative or membranous LN between 1995 and 2013 were identified from the Barts Lupus Centre database; baseline characteristics were compared with each RCT's entry criteria to assess hypothetical inclusion or exclusion. RESULTS: Of 363 articles, 33 RCTs met inclusion criteria. Of 137 patients newly diagnosed with LN (111 with proliferative/mixed proliferative and 26 with pure membranous LN), 32% would have been excluded from RCT entry (range 8%-73%). The main reasons for exclusion would have been too severe disease, too mild disease, or prior immunosuppressant use, which were exclusion criteria in 26, 20, and 22 RCTs, respectively. A total of 27 patients with LN (20%) were re-biopsied due to flare; 68% of these would have been ineligible to enter RCTs. CONCLUSION: Published RCTs do not truly reflect the heterogeneity of patients with LN in routine practice at our lupus center. The external validity of RCTs could be improved by including more representative patient cohorts. RCTs should be used as a guide but consideration should be given to similarities between individual patients and the characteristics of the trial cohorts before treatment decisions being made.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Pakozdi A, Rajakariar R, Pyne D, et al. Systematic Review and the External Validity of Randomized Controlled Trials in Lupus Nephritis. Kidney Int Rep. 2017. PMID: 29725644. doi:10.1016/j.ekir.2017.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。